Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats

Hypertension Research

Volumn 34, Issue 5, 2011, Pages 584-591

  Kimura, Shinpei ^a   Ito, Masahiro ^a   Tomita, Makoto ^a   Hoyano, Makoto ^a   Obata, Hiroaki ^a   Ding, Limin ^a   Chinushi, Masaomi ^a   Hanawa, Haruo ^a   Kodama, Makoto ^a   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

atrial fibrillation; atrial remodeling; mineralocorticoid receptor; Rac1

Indexed keywords

4 HYDROXYNONENAL; EPLERENONE; MINERALOCORTICOID RECEPTOR; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DIETARY INTAKE; FIBROSING ALVEOLITIS; HEART ATRIUM FIBRILLATION; HEART ATRIUM HYPERTROPHY; HEART ATRIUM PACING; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HIGH SODIUM INTAKE; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE ANTAGONISTS; ANIMALS; ATRIAL FIBRILLATION; CARDIOMEGALY; FIBROSIS; HEART ATRIA; HYPERTENSION; MALE; MYOCARDIUM; OXIDATIVE STRESS; RAC1 GTP-BINDING PROTEIN; RATS; RATS, INBRED DAHL; RECEPTORS, MINERALOCORTICOID; SODIUM CHLORIDE, DIETARY; SPIRONOLACTONE;

EID: 79955597333     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.277     Document Type: Article

References (38)

1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042-1046. (Pubitemid 39319000)
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952. (Pubitemid 28446646)
3. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364. (Pubitemid 35223606)
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-988.
5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285: 2370-2375. (Pubitemid 32424106)
6. AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J 2002; 143: 991-1001.
7. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839. (Pubitemid 40789940)
8. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol 2008; 1: 62-73.
9. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
10. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. (Pubitemid 36384098)
11. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005; 111: 420-427. (Pubitemid 40204425)
12. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-664. (Pubitemid 43740235)
13. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120: 893-901. (Pubitemid 23002899)
14. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269: E657-E662.
15. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836. (Pubitemid 35397623)
16. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379-388. (Pubitemid 37163454)
17. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J, Oliver-Krasinski J, Baliga R, Wang J, Siwik DA, Singh K, Pagano P, Colucci WS, Sawyer DB. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 2001; 89: 453-460. (Pubitemid 34132662)
18. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol 2003; 35: 615-621. (Pubitemid 36677445)
19. Hordijk PL. Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006; 98: 453-462.
20. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108: 1429-1437. (Pubitemid 33091980)
21. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J, Takai Y, Fujita T. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-1376.
22. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008; 149: 1009-1014. (Pubitemid 351397957)
23. Mitsuma W, Ito M, Kodama M, Fuse K, Okamura K, Minagawa S, Kato K, Hanawa H, Toba K, Nakazawa M, Aizawa Y. Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis. Biochem Biophys Res Commun 2006; 344: 987-994.
24. Hoyano M, Ito M, Kimura S, Tanaka K, Okamura K, Komura S, Mitsuma W, Hirono S, Chinushi M, Kodama M, Aizawa Y. Inducibility of atrial fibrillation depends not on inflammation but on atrial structural remodeling in rat experimental autoimmune myocarditis. Cardiovasc Pathol 2010; 19: e149-e157.
25. Okamura K, Ito M, Tanaka K, Chinushi M, Adachi T, Mitsuma W, Hirono S, Nakazawa M, Kodama M, Aizawa Y. Effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats. Pharmacology 2009; 83: 360-366.
26. Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 2004; 110: 412-418. (Pubitemid 38993850)
27. Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E, Beaufils P, Delcayre C, Hatem SN. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005; 26: 2193-2199. (Pubitemid 41408006)
28. Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 2006; 17: 534-541.
29. Wahed MI, Watanabe K, Ma M, Yamaguchi K, Takahashi T, Tachikawa H, Kodama M, Aizawa Y. Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. Pharmacology 2005; 73: 81-88. (Pubitemid 40082318)
30. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-998. (Pubitemid 35416635)
31. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-2092. (Pubitemid 41408600)
32. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-2028. (Pubitemid 350087568)
33. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184. (Pubitemid 27344221)
34. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-3010. (Pubitemid 37553570)
35. Asselbergs FW, van den Berg MP, Diercks GF, van Gilst WH, Van Veldhuisen DJ. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol 2005; 98: 73-77. (Pubitemid 40169856)
36. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47: 1084-1093. (Pubitemid 44289165)
37. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K, Ogawa H. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104: 137-139. (Pubitemid 32655827)
38. Adam O, Frost G, Custodis F, Sussman MA, Schäfers HJ, Böhm M, Laufs U. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 2007; 50: 359-367. (Pubitemid 47064499)